Embedding force-sensitive microbeads into blood clots for reporting platelet function.

Force-sensitive microbeads embedded in platelet clots offer a rapid and sensitive method for evaluating platelet function, addressing the limitations of current tests by using fluorescence to measure aggregation strength with minimal blood volume.

JP2026537448APending Publication Date: 2026-11-09UNIVERSITY OF CINCINNATI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026525124
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-27
Filing Date
2024-10-28
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Current platelet function tests suffer from high rates of false negatives or false positives and require significant blood volumes, necessitating invasive venous blood collection.

Method used

Embedding force-sensitive microbeads coated with tension sensors into platelet clots to measure platelet aggregation strength by fluorescence signal, allowing for rapid analysis of platelet function using a small blood sample.

Benefits of technology

Provides high sensitivity and specificity in platelet function testing, requiring only 0.2 mL of blood, with analysis times of 5 to 10 minutes, and enabling direct fluorescence reading without amplification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026537448000001_ABST
    Figure 2026537448000001_ABST
Patent Text Reader

Abstract

A method for determining platelet aggregation strength is provided. This method includes the steps of: embedding microbeads coated with tension sensors into a platelet clot; and reporting the platelet aggregation strength by observing a fluorescence signal from the microbeads corresponding to the contractile force acting on the tension-sensor-coated microbeads. In one embodiment, platelet aggregation strength is used as a biomechanical marker for evaluating platelet function. In another embodiment, the fluorescence signal can be directly read by a plate reader.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS 0001 This application claims priority to U.S. Provisional Application No. 63 / 546,023 filed on October 27, 2023, the entire disclosure of which is incorporated herein by reference in its entirety.

[0002] 0002 The present invention relates to a method for diagnosing platelet disorders. BACKGROUND ART

[0003] 0003 Platelets, also known as thrombocytes, are tiny blood cells essential for the blood clotting process. A platelet disorder in a patient may lead to serious consequences, such as increased bleeding risk, elevated clotting tendency (thrombocytosis), vulnerability to infectious diseases, and potential organ damage. Hematologists frequently perform platelet function tests to assess the effectiveness of a patient's platelets. However, current methods such as platelet aggregometry and flow cytometry mainly examine chemicals secreted from platelets or measure changes in absorbance caused by platelet aggregation. These techniques have the problem of a significant rate of false negatives or false positives. Furthermore, they typically require a considerable volume of blood (>5 mL), thus necessitating venous blood collection. Overall, there is a high demand for a convenient, reliable, and rapid platelet testing method that only requires a small volume of blood sample. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEMS

[0004] 0004 Certain exemplary embodiments of the present invention are described below. It should be understood that these embodiments are presented merely to provide the reader with a brief summary of specific forms that the present invention may take, and are not intended to limit the scope of the present invention. In fact, the present invention may include various embodiments that may not be explicitly described below.

[0005]

[0005] In one aspect of the present invention, a method for determining platelet aggregation strength is provided. The method includes the steps of embedding microbeads coated with tension sensors into a platelet blood clot, and reporting the platelet aggregation strength by observing a fluorescence signal from the microbeads corresponding to the contractile force applied to the microbeads coated with tension sensors. In one embodiment, platelet aggregation strength is used as a biomechanical marker for evaluating platelet function. In another embodiment, the fluorescence signal can be read directly by a plate reader. In one embodiment, platelet aggregation strength is determined using approximately 10 μL or less of the subject's blood.

[0006]

[0006] In another embodiment, platelet aggregation strength is determined with an analysis time of 5 to 10 minutes. In one embodiment, the tension sensor is an integrated tension sensor (ITS). In another embodiment, the microbeads comprise a material selected from the group consisting of polystyrene and polyacrylamide. In one embodiment, the diameter of the microbeads is 3 to 5 μm. In another embodiment, the tension sensor is bound to the microbeads by the interaction of streptavidin and biotin. In one embodiment, the microbeads are used in a ratio of microbeads to platelets ranging from 1:10 to 1:1000.

[0007]

[0007] In another aspect of the present invention, microbeads coated with tension sensors are provided. The microbeads are spherical polystyrene spheres having a spherical surface to which the tension sensors are bonded. In one embodiment, the tension sensor is an embedded tension sensor (ITS). In another embodiment, each microbead has between 10,000 and 100,000 ITS molecules bonded to it.

[0008]

[0008] In another aspect of the present invention, microbeads coated with tension sensors are provided. The microbeads are spherical spheres made of polyacrylamide, with tension sensors bonded to the spherical surface. In one embodiment, the tension sensor is an embedded tension sensor (ITS). In another embodiment, each microbead has 10,000 to 100,000 ITS molecules bonded to it.

[0009]

[0009] The above summary and the following detailed description relating to preferred embodiments of this application will be better understood when read in conjunction with the accompanying drawings. [Brief explanation of the drawing]

[0010] [Figure 1A]

[0010] Figure 1A is a schematic diagram showing a double-stranded DNA-based tension sensor modified with a quencher, a dye (Atto647N or other dye), and a ligand (RGD peptide) that induces platelet adhesion. [Figure 1B]

[0011] Figure 1B is a schematic diagram showing the process of obtaining the adhesion pattern of platelets. [Figure 1C]

[0012] Figure 1C is a series of images showing typical platelet adhesion strength 1 to 10 minutes after platelets are attached to the ITS surface. [Figure 2]

[0013] Figure 2 is a schematic diagram showing that microbeads coated with ITS (3-5 μm in diameter) interact with platelets, reporting the contractile force of the platelets by fluorescence emission, and then mixing the ITS-coated microbeads with a platelet solution and adding it to a 96-well plate. [Figure 3]

[0014] Figure 3 is a graph showing the fluorescence signals of PRP, PPP, and PRP (tyrofiban). [Figure 4]

[0015] Figure 4 is a graph showing that force-sensing microspheres report aggregation force in platelet thrombi treated with aspirin (acetylsalicylic acid, ASA), a common antiplatelet drug. This result demonstrates that ITS-coated microspheres respond smoothly to antiplatelet drug treatment. [Modes for carrying out the invention]

[0011]

[0022] This specification provides details of one or more embodiments of the disclosed subject matter. Modifications of the embodiments described herein, and other embodiments, will become apparent to those skilled in the art upon consideration of the information provided herein.

[0012]

[0023] This disclosure may be more readily understood by referring to the following detailed descriptions of embodiments in conjunction with the accompanying drawings that form part of this disclosure. This application is not limited to any specific apparatus, method, condition, or parameter described and / or shown herein, and the terms used herein are intended to illustrate specific embodiments as examples and should be understood as not intended to limit them. Also, in some embodiments, as used herein, including in the claims of the appendix, the singular forms “a,” “an,” and “the” include the plural, and when referring to a specific numerical value, it shall include at least that specific numerical value unless otherwise indicated in the context. Ranges may be expressed herein as “about” or “approximately” a certain value to and / or “about” or “approximately” another specific value. Where such ranges are given, another embodiment includes from and / or to one specific value. Similarly, where a value is expressed as an approximate value using the preceding term “about,” it will be understood that a particular value constitutes another embodiment.

[0013]

[0024] In this specification, the term “about” means, when referring to a value, or mass, weight, time, volume, pH, size, concentration, or percentage, to include a variation from a particular amount of ±20% in some embodiments, ±10% in some embodiments, ±5% in some embodiments, ±1% in some embodiments, ±0.5% in some embodiments, and ±0.1% in some embodiments, so that such variation is appropriate for carrying out the disclosed method.

[0014]

[0025] Any maximum numerical limitation provided throughout this specification should be understood to include all lower numerical limitations as if they were explicitly stated herein. Any minimum numerical limitation provided throughout this specification shall include all higher numerical limitations as if they were explicitly stated herein. Any numerical range provided throughout this specification shall include all narrower numerical ranges that fall within such wider ranges as if all such narrower numerical ranges were explicitly stated herein.

[0015]

[0026] This invention relates to force-sensitive microbeads (also known as "microspheres") and a method for evaluating the health of platelets using these microbeads. These micron-sized beads can be made from various materials, such as polystyrene, and are endowed with molecular force sensor functionality. The beads are mixed with a patient's platelet sample (e.g., platelet-rich plasma or platelet solution). Healthy platelets aggregate with the beads and exert a contractile force that induces fluorescence emission in the beads. The fluorescence signal is then imaged using a microscope or quantified by a plate reader. These fluorescence signals are used as indicators of platelet health.

[0016]

[0027] Modern platelet function tests often lack sensitivity and specificity when detecting platelet dysfunction and related problems. The force-sensitive microbeads and microbead-based platelet aggregation force analysis of the present invention significantly improve upon this technique. This analysis is easy to perform, requires only 0.2 mL of platelet sample, and offers high sensitivity and specificity. It has been proven that platelet aggregation force can be effectively measured and platelet dysfunction detected through force-induced fluorescence signals.

[0017] The power of platelets

[0028] To achieve high sensitivity and specificity, the method described in this invention quantifies platelet force as a key indicator for evaluating platelet health. Force plays a crucial role in substantially all aspects of platelet function. Upon injury, platelets first adhere to the exposed subendothelial layer via integrins, which transmit force to facilitate stable adhesion and activation of platelets. Activated platelets gather additional platelets to form a thrombus and clot. Platelets further contract within the thrombus and clot to stabilize the structure and ultimately stop bleeding. Throughout this process, the force transmitted by integrins (integrin α2β1 and integrin αIIbβ3) plays a decisive role in platelet adhesion, activation, aggregation, and contraction. Therefore, the force transmitted by integrins is essential for normal platelet function. The force-sensing microbeads described in this invention report platelet aggregation force by fluorescence emission, indicating platelet health with high sensitivity and specificity. In one embodiment, platelet analysis based on microbeads requires only 0.2 mL of platelet sample, which is substantially less than the amount required for conventional platelet function tests.

[0018]

[0029] The force-sensing microbeads of the present invention enable testing of platelet aggregation force (platelet force assay). As shown in Figures 1A and 1B, a tension sensor (built-in tension sensor, or referred to as ITS) can be used to detect and image the adhesion force of platelets on a flat glass surface. When the molecular force generated by platelets breaks the double-stranded DNA structure of ITS and the fluorescent dye on ITS is unquenched, ITS emits fluorescence, whereby the force signal is converted into a fluorescent signal. The structure and working principle of ITS are shown in Figure 1A. The procedure for imaging platelet adhesion is shown in Figure 1B. Figure 1C shows a typical image of platelet force after platelets are allowed to adhere to the ITS surface for 1 to 10 minutes.

[0019] Built-in tension sensor

[0030] The built-in tension sensor (ITS) directly converts molecular tension into a fluorescent signal (force-fluorescence emission conversion). As a molecular linker, ITS is initially non-fluorescent and can be activated to permanently emit fluorescence under tension. Since the tension threshold required for ITS activation can be adjusted in the range of 10 to 60 piconewtons (pN), molecular tension at different force levels can be selectively visualized. On the surface tethered with integrin ligands by ITS, the tension of integrins in platelets activates ITS, which can be directly mapped by fluorescence imaging without the need for post-modeling and calculations normally required in force-strain approaches.

[0020]

[0031] ITS is a double-stranded DNA (dsDNA) with 18 base pairs. The sequences and modifications of an embodiment of single-stranded DNA for ITS synthesis are shown below. ThioMC6-D / indicates thiol binding to the 5' end of DNA. / BiosG / and / Bio / indicate DNA modifications with biotin bound to the 5' end and 3' end, respectively. BHQ2 is a Black Hole Quencher. DNA sequences were selected and analyzed using a DNA analysis tool available from the company Integrated DNA Technologies (IDTDNA) to minimize the possibility of self-dimer and hairpin formation in single-stranded DNA.

[0021]

[0032] 5'- / ThioMC6-D / SEQ.ID1 / BHQ2 / -3'

[0033] SEQ.ID1:GGG CGG CGA CCT CAG CAT

[0034] 5'- / BiosG / T / iCy3 / SEQ.ID2 / -3'

[0035] SEQ.ID2:ATG CTG AGG TCG CCG CCC

[0036] 5'- / Cy3 / SEQ.ID2 / Bio / -3'

[0037] 5'- / Alexa647 / SEQ.ID2 / Bio / -3'

[0038] The amine-containing cyclic peptide RGD (PCI-3696-PI, Peptides International) was conjugated to a thiol-modified DNA strand. The cyclic RGD possesses a PEG linker, which facilitates RGD's access to integrins on the cell membrane. Conjugation was performed according to a previously published protocol. Briefly, the thiol modification at the 5' end of the DNA was deprotected with TCEP (tris(2-carboxyethyl)phosphine hydrochloride) and reacted with the maleimide group of the heterolinker SMCC-sulfo (22622, Thermos Scientific). The other end of SMCC-sulfo is an NHS ester (N-hydroxysuccinimide ester), which reacts with the amine of RGD. RGD-conjugated DNA was purified by electrophoresis. The 12pN and 54pN ITS used herein were assembled by hybridizing two single-stranded DNA strands in a concentration ratio of 1.1:1 (quencher strand: fluorescent dye-containing DNA strand).

[0022]

[0039] ITS with a threshold of 54 pN (having a Cy3-BHQ2 pair)

[0040] 5'- / RGD / SEQ.ID1 / BHQ2 / -3'

[0041] 5'- / BiosG / T / iCy3 / SEQ.ID2 / -3'

[0042] ITS with a threshold of 12pN (having a Cy3-BHQ2 pair)

[0043] 5'- / RGD / SEQ.ID1 / BHQ2 / -3'

[0044] 5'- / Cy3 / SEQ.ID2 / Bio / -3'

[0045] ITS with a threshold of 12pN (having an Alexa647-BHQ2 pair)

[0046] 5'- / RGD / SEQ.ID1 / BHQ2 / -3'

[0047] 5'- / Alexa647 / SEQ.ID2 / Bio / -3'

[0023] Preparation of force-sensitive microbeads

[0048] As shown in Figure 1A, in one embodiment of the present invention, ITS is coated onto microbeads at a density of 100,000 ITS per bead. This ITS structure consists of 18-base-pair double-stranded DNA and is modified with biotin, a fluorescent dye (e.g., Atto647N), a quencher (e.g., Black Hole Quencher), and an integrin ligand (e.g., RGD peptide). The ITS coating of the beads is achieved by mixing a bead solution with an ITS solution, and the ITS is immobilized on the bead surface by the interaction of biotin and streptavidin.

[0024]

[0049] The present invention quantifies the contractile force of platelets using microbeads coated with ITS. In one embodiment, the microbeads have a diameter of 3–5 μm, similar in size to platelets. These microbeads are made from polystyrene beads (rigid), polyacrylamide beads (flexible), or other materials. The microbeads are coated with ITS through the interaction of streptavidin and biotin. It is estimated that 10,000–100,000 ITS molecules are bound to a single microbead. Force-sensing microbeads can be prepared on a large scale. The microbead solution serves as a pre-prepared reagent for platelet force analysis.

[0025] Embedding force-sensitive microbeads into platelet clots for reporting platelet function.

[0050] Microbeads coated with the above-mentioned ITS are mixed with platelet-rich plasma (or platelets resuspended in cell culture medium) and a platelet agonist such as ADP (adenosine diphosphate). The ratio of microbeads to platelets ranges from 1:10 to 1:1000, depending on the desired final fluorescence signal intensity. The microbeads and platelets form a platelet clot with the microbeads embedded within it. As platelets adhere to the microbeads and the clot contracts, a contractile force is generated on the microbeads, ultimately activating the ITS on the microbeads and causing them to fluoresce. The fluorescent microbeads can be imaged using confocal microscopy to examine the contractile force distribution in three-dimensional (3D) space, or the overall platelet aggregation force signal can be reported by simply reading them with a plate reader in a 96-well plate. The large contact surface area provided by the microbeads embedded in the clot increases the fluorescence intensity of the platelet aggregation force signal, making it possible to directly read such force signals with a plate reader.

[0026]

[0051] Referring to Figure 2, section A of this schematic diagram shows that polystyrene microbeads (or other materials such as acrylamide) are coated with embedded tension sensors (ITS). In one embodiment, each microbead has approximately 100,000 ITS molecules bound to it. The ITS binds to integrins on the platelet membrane, and the integrins then transmit the platelet force to the ITS, activating it and causing it to fluoresce. The ITS structure is double-stranded DNA modified with an integrin peptide ligand and a pair of fluorescent dye and quencher (e.g., Atto647N and a black hole quencher). The ITS is immobilized on the bead via covalent bonding or biotin-avidin interaction.

[0027]

[0052] Section B of the schematic diagram shows microbeads coated with ITS mixed with platelets in a ratio of approximately 1:10. This mixture is added to a plate well or petri dish. The microbeads and platelets spontaneously aggregate. Section C of the schematic diagram shows that the aggregated platelets transmit force to the ITS on the microbeads, activating the ITS by separating DNA and removing the quencher, thus causing it to fluoresce. Section D of the schematic diagram shows that the fluorescence intensity of the microbeads is imaged using a microscope or quantified using a plate reader. The fluorescence signal is used to assess the health of the platelets.

[0028]

[0053] In summary, the preparation procedure for this platelet strength analysis can be as simple as mixing a microbead solution with a platelet sample. After 20 minutes at room temperature, the sample is imaged using a microscope or quantified by a plate reader, thus having low equipment or laboratory environment requirements.

[0029] usefulness

[0054] Since platelet aggregation is a critical step in hemostasis, platelet aggregation strength, reported by 3D fluorescence imaging or the overall fluorescence signal intensity of microbeads embedded in platelet clots, serves as a biomechanical benchmark for evaluating normal platelet function. This method can find applications in a variety of clinical situations. Examples of clinical situations include evaluating the quality of platelets from blood donors, evaluating the quality of long-term stored platelet preparations, analyzing a patient's blood coagulation ability to determine the need for platelet transfusions, and initial analysis of platelet function in patients suspected of having bleeding disorders.

[0030] The method of the present invention has numerous advantages. Firstly, it requires only a very small amount of blood, ranging from 10 μL to 100 μL. The blood sample can be obtained by pricking a fingertip, which is a less invasive procedure than venous blood collection. Secondly, the method is also rapid, with a total analysis time of 5 to 10 minutes. This is because the signals of platelet adhesion and contractility are already quite large within 5 minutes of attaching the platelets to the plane. Thirdly, the microbeads embedded in the platelet clot have a much larger contact surface area with the platelets compared to a two-dimensional planar glass surface, thus generating a strong fluorescence signal that can be directly read with a platelet reader without prior signal amplification. [Examples]

[0031] Example 1 - Preparation of Analytes

[0055] Analytes were prepared by mixing 20 μL of force-sensitive microbeads (0.5% v / v concentration) with 180 μL of platelet-rich plasma (PRP) in phosphate-buffered saline (PBS). The mixture was then added to 13 mm diameter wells in a glass-bottomed Petri dish or to wells in a 96-well plate. After reacting at room temperature for 20 minutes, platelets aggregated with the force-sensitive microbeads. Healthy platelets also exerted force on the beads, activating ITS on the beads and causing fluorescence emission. The fluorescence activation is irreversible, permanently recording platelet aggregation force. Samples were imaged by microscopy or analyzed using a plate reader. Fluorescence intensity was recorded and used as a signal indicating the health of the platelets. The normal range of fluorescence intensity was pre-determined using a sample group of healthy platelets.

[0032] Example 2 - Verification of the ability of force-sensitive microbeads in reporting platelet aggregation force.

[0056] Force-sensitive microbeads have been shown to effectively report platelet aggregation force. In a typical analyte, the beads were mixed with platelet-rich plasma (PRP) and added to a Petri dish. The microbeads clumped together within the platelet aggregates and emitted fluorescence. In contrast, microbeads in PRP treated with tirofiban, a potent platelet force inhibitor, did not emit a fluorescence signal. Similarly, microbeads in platelet-poor plasma (PPP, platelet-removed plasma) also did not emit a fluorescence signal. The fluorescence signal from microbeads in healthy platelet samples was significantly stronger than that from PPP (platelet-removed plasma) or PRP in which platelet function was inhibited by tirofiban. These results (shown in Figure 3) demonstrate that force-sensitive microbeads can reliably report platelet aggregation force within platelet aggregates (thrombi).

[0033] Example 3 - Verification of the performance of force-sensing beads in reporting platelet health status

[0057] The performance of the platelet strength analysis described in this application was validated using platelets treated with acetylsalicylic acid (ASA, also known as aspirin, which has been commonly used as an antiplatelet agent to reduce thrombotic tendencies). The platelet strength analysis was validated using PRP treated with acetylsalicylic acid (ASA, also known as aspirin). As a positive control, force-sensitive microbeads were mixed with platelet-rich plasma (PRP). A considerable number of microbeads were spontaneously incorporated into platelet aggregates, where they fluoresced, appearing as red. The fibrin network, which aids in blood coagulation, is shown in green. A second test was performed using PRP treated with 100 μM aspirin for 1 hour prior to the strength analysis. Microbeads were also incorporated into the platelet clots. In a third test, PRP treated with 200 μM aspirin for 1 hour prior to the analysis was used. In this case, no platelet aggregation was observed.

[0034]

[0058] The fluorescence intensity of individual microbeads was recorded under three different conditions. The results (shown in Figure 4) show that the fluorescence intensity of microbeads in aspirin-treated platelet samples was significantly lower than that of the control. These results clearly demonstrate the feasibility of force-sensitive microbeads in reporting platelet health.

[0035]

[0059] All cited documents are incorporated herein by reference. No citation of any document shall be construed as an admission that it is prior art to the present invention.

[0036]

[0060] Furthermore, where the terms “includes” and / or “contains” are used in the description of various embodiments, a person skilled in the art will understand that in some specific cases a certain embodiment can be described alternatively using the expression “essentially consists of” or “consists of.”

[0037]

[0061] Although specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other modifications and alterations are possible without departing from the spirit and scope of the invention. Accordingly, it is intended that any such modifications and alterations within the scope of the invention be included in the claims of the appendix.

[0038] array

[0062] SEQ.ID1:GGG CGG CGA CCT CAG CAT

[0063] SEQ.ID2:ATG CTG AGG TCG CCG CCC

Claims

1. A method for determining platelet aggregation strength, comprising the steps of: embedding microbeads coated with tension sensors into a platelet blood clot; and observing a fluorescent signal from the microbeads corresponding to the contractile force applied to the microbeads coated with tension sensors, and reporting the platelet aggregation strength.

2. The method according to claim 1, wherein the platelet aggregation force is used as a biomechanical marker for evaluating platelet function.

3. The method according to claim 1, wherein the fluorescence signal can be directly read by a plate reader.

4. The method according to claim 1, wherein platelet aggregation strength is determined using approximately 10 μL or less of the subject's blood.

5. The method according to claim 1, wherein platelet aggregation ability is determined within an analysis time of 5 to 10 minutes.

6. The method according to claim 1, wherein the tension sensor is an embedded tension sensor (ITS).

7. The method according to claim 1, wherein the microbeads comprise a material selected from the group consisting of polystyrene and polyacrylamide.

8. The method according to claim 1, wherein the diameter of the microbeads is 3 to 5 μm.

9. The method according to claim 1, wherein the tension sensor is bound to the microbeads by the interaction of streptavidin and biotin.

10. The method according to claim 1, wherein the microbeads are used in a ratio of microbeads to platelets ranging from 1:10 to 1:1000.

11. Microbeads coated with tension sensors, comprising a spherical polystyrene sphere having a spherical surface, wherein the tension sensor is bonded to the spherical surface.

12. The tension sensor according to claim 11, wherein the tension sensor is an embedded tension sensor (ITS).

13. The tension sensor according to claim 12, wherein each of the microbeads has 10,000 to 100,000 ITS molecules bound to it.

14. Microbeads coated with tension sensors, comprising a spherical polyacrylamide sphere having a spherical surface, wherein the tension sensor is bonded to the spherical surface.

15. The tension sensor according to claim 14, wherein the tension sensor is an integrated tension sensor (ITS).

16. The tension sensor according to claim 15, wherein each of the microbeads has 10,000 to 100,000 ITS molecules bound to it.